Lung Cancer | Specialty

Variants of NTRK Fusions in Solid Tumors

May 21st 2020

Role of NTRK Inhibitors

May 21st 2020

ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting

May 21st 2020

Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 20th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Savvides on the Utility of Immunotherapy in Lung Cancer

May 19th 2020

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

Dr. Natale on the Evolution of Immunotherapy in NSCLC

May 15th 2020

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 14th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 13th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery.

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery, without sacrificing quality of care.

FDA Approves Selpercatinib for RET+ NSCLC and Thyroid Cancers

May 9th 2020

The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Sintilimab Regimen Improves PFS in Frontline Squamous NSCLC

May 7th 2020

Adding the PD-1 inhibitor sintilimab injection to gemcitabine and platinum-based chemotherapy improved progression-free survival as a frontline treatment in squamous non–small cell lung cancer.

FDA Approves Capmatinib for METex14+ NSCLC

May 6th 2020

The FDA has approved capmatinib for the treatment of patients with non–small cell lung cancer.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

May 5th 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Garon Sheds Light on CNS Activity With Capmatinib in MET Exon 14+ NSCLC

May 2nd 2020

Edward B. Garon, MD, MS, discusses the importance of the GEOMETRY mono-1 study in patients with advanced NSCLC who harbor MET exon 14 skipping mutations.